We have developed chelator-free copper-64-incorporated iron oxide (IO) nanoparticle (NPs) which have both magnetic and radioactive properties being applied to positron emission tomography (PET)-magnetic resonance imaging (MRI). We have found that the IO nanoparticles composed of radioactive isotope 64Cu may act as a contrast agent being a diagnostic tool for PET as well as a good T2 MRI nanoprobe due to their good r2/r1 ratio. Furthermore, we demonstrate that the 64Cu incorporation at the core of core-shell-structured IO NPs exhibits a good in vivo stability, giving us an insightful strategy for the design of a contrast agent for the PET-MRI system.
1 October 2015 in Journal of the Korean Physical Society
We designed a ridge-filter-type modulator suitable for 100-MeV pulsed proton beam modulation. It can be applied to a variety of experiments, such as in medical technology and space technology proton beam modulation from the surface to an 8-cm depth. We also designed a 2-cm spread-out Bragg peak for cancer research using a small experimental animal orthotopic tumor model. The minimum thickness of the range modulator is specified as 2 mm for the mechanical support, and the maximum thickness in the 8-cm and 2-cm SOBP are specified as 40 mm and 12 mm, respectively. The ridge interval and the drift distance are 8 mm and 30 cm, respectively. The design was carried out using the Stopping and Range of Ions in Matter and the Monte Carlo N-particle Extended codes. The results show that the two-dimensional dose distributions of the two range modulators are uniform.
Recent studies have identified highly tumorigenic cells with stem cell-like characteristics in human cancers, termed cancer stem cells (CSCs). CSCs are resistant to conventional radiotherapy and chemotherapy owing to their high DNA repair ability and oncogene overexpression. However, the mechanisms regulating CSC radio-resistance, particularly proton beam resistance, remain unclear. We isolated CSCs from the breast cancer cell lines MCF-7 and MDA-MB-231, which expressed the characteristic breast CSC membrane protein markers CD44+/CD24-/low, and irradiated the CSCs with pulsed proton beams. We confirmed that CSCs are resistant to pulsed proton beams and showed that treatment with p38 and ERK inhibitors reduced CSC radioresistance. Based on these results, BCSC radio-resistance can be reduced during proton beam therapy by co-treatment with ERK1/2 or p38 inhibitors, representing a novel approach for breast cancer therapy.